{"entity":{"type":"insider","cik":"0001834021","url":"/insider/0001834021","json_url":"/insider/0001834021.json","name":"Kirn David","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":27,"n_filings":14,"first":"2022-12-19","last":"2026-08-21","span_basis":"filed_date"},"name_variants":[{"name":"Kirn David","source":"filing","n_filings":14,"first_seen":"2022-12-19","last_seen":"2026-08-21"}],"transactions":[{"id":9300193,"accession":"0001193125-26-361096","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-361096","line_url":"/filing/0001193125-26-361096","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001834021","owner_name":"Kirn David","owner_display_name":"Kirn David","owner_url":"/insider/0001834021","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":69076.0,"shares_display":"69,076","price_per_share":15.754723355434594,"price_display":"15.75","price_state":"stated","total_value":1088273.2705,"total_display":"1,088,273.27","total_whole":"1,088,273","shares_owned_after":851746.0,"shares_owned_after_display":"851,746","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-19","filed_date":"2026-08-21","scope":"insider","n_lines":2},{"id":6089365,"accession":"0001193125-26-335115","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-335115","line_url":"/filing/0001193125-26-335115#line-1","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001834021","owner_name":"Kirn David","owner_display_name":"Kirn David","owner_url":"/insider/0001834021","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":26842.0,"shares_display":"26,842","price_per_share":10.2301,"price_display":"10.23","price_state":"stated","total_value":274596.3442,"total_display":"274,596.34","total_whole":"274,596","shares_owned_after":844895.0,"shares_owned_after_display":"844,895","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-04","filed_date":"2026-08-05","scope":"insider"},{"id":5930658,"accession":"0001193125-26-333014","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-333014","line_url":"/filing/0001193125-26-333014#line-1","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001834021","owner_name":"Kirn David","owner_display_name":"Kirn David","owner_url":"/insider/0001834021","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12415.0,"shares_display":"12,415","price_per_share":10.0461,"price_display":"10.05","price_state":"stated","total_value":124722.3315,"total_display":"124,722.33","total_whole":"124,722","shares_owned_after":871737.0,"shares_owned_after_display":"871,737","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-03","filed_date":"2026-08-04","scope":"insider"},{"id":5841124,"accession":"0001834021-26-000004","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001834021-26-000004","line_url":"/filing/0001834021-26-000004","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001834021","owner_name":"Kirn David","owner_display_name":"Kirn David","owner_url":"/insider/0001834021","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15725.0,"shares_display":"15,725","price_per_share":12.033883567567567,"price_display":"12.03","price_state":"stated","total_value":189232.8191,"total_display":"189,232.82","total_whole":"189,233","shares_owned_after":884594.0,"shares_owned_after_display":"884,594","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-10","filed_date":"2026-07-14","scope":"insider","n_lines":2},{"id":5841122,"accession":"0001834021-26-000004","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001834021-26-000004","line_url":"/filing/0001834021-26-000004#line-1","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001834021","owner_name":"Kirn David","owner_display_name":"Kirn David","owner_url":"/insider/0001834021","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":42608.0,"shares_display":"42,608","price_per_share":12.8656,"price_display":"12.87","price_state":"stated","total_value":548177.4848,"total_display":"548,177.48","total_whole":"548,177","shares_owned_after":899877.0,"shares_owned_after_display":"899,877","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-09","filed_date":"2026-07-14","scope":"insider"},{"id":5771588,"accession":"0001834021-26-000002","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001834021-26-000002","line_url":"/filing/0001834021-26-000002#line-1","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001834021","owner_name":"Kirn David","owner_display_name":"Kirn David","owner_url":"/insider/0001834021","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":114746.0,"shares_display":"114,746","price_per_share":10.4653,"price_display":"10.47","price_state":"stated","total_value":1200851.3138,"total_display":"1,200,851.31","total_whole":"1,200,851","shares_owned_after":942485.0,"shares_owned_after_display":"942,485","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-22","filed_date":"2026-06-23","scope":"insider"},{"id":5751273,"accession":"0001193125-26-253740","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-253740","line_url":"/filing/0001193125-26-253740#line-1","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001834021","owner_name":"Kirn David","owner_display_name":"Kirn David","owner_url":"/insider/0001834021","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1922.0,"shares_display":"1,922","price_per_share":10.0197,"price_display":"10.02","price_state":"stated","total_value":19257.8634,"total_display":"19,257.86","total_whole":"19,258","shares_owned_after":1057231.0,"shares_owned_after_display":"1,057,231","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-01","filed_date":"2026-06-02","scope":"insider"},{"id":2827287,"accession":"0000950170-24-083303","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-083303","line_url":"/filing/0000950170-24-083303#line-3","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001834021","owner_name":"Kirn David","owner_display_name":"Kirn David","owner_url":"/insider/0001834021","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12923.0,"shares_display":"12,923","price_per_share":22.4869,"price_display":"22.49","price_state":"stated","total_value":290598.2087,"total_display":"290,598.21","total_whole":"290,598","shares_owned_after":1059153.0,"shares_owned_after_display":"1,059,153","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-10","filed_date":"2024-07-12","scope":"insider"},{"id":2637493,"accession":"0000950170-24-077944","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-077944","line_url":"/filing/0000950170-24-077944#line-2","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001834021","owner_name":"Kirn David","owner_display_name":"Kirn David","owner_url":"/insider/0001834021","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12930.0,"shares_display":"12,930","price_per_share":23.1022,"price_display":"23.10","price_state":"stated","total_value":298711.446,"total_display":"298,711.45","total_whole":"298,711","shares_owned_after":1059153.0,"shares_owned_after_display":"1,059,153","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-24","filed_date":"2024-06-26","scope":"insider"},{"id":2673924,"accession":"0000950170-24-014091","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-014091","line_url":"/filing/0000950170-24-014091#line-1","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001834021","owner_name":"Kirn David","owner_display_name":"Kirn David","owner_url":"/insider/0001834021","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":92001.0,"shares_display":"92,001","price_per_share":27.1282,"price_display":"27.13","price_state":"stated","total_value":2495821.5282,"total_display":"2,495,821.53","total_whole":"2,495,822","shares_owned_after":1059153.0,"shares_owned_after_display":"1,059,153","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-08","filed_date":"2024-02-12","scope":"insider"},{"id":2065949,"accession":"0000950170-24-007477","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-007477","line_url":"/filing/0000950170-24-007477#line-1","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001834021","owner_name":"Kirn David","owner_display_name":"Kirn David","owner_url":"/insider/0001834021","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5696.0,"shares_display":"5,696","price_per_share":18.4079,"price_display":"18.41","price_state":"stated","total_value":104851.3984,"total_display":"104,851.40","total_whole":"104,851","shares_owned_after":1151154.0,"shares_owned_after_display":"1,151,154","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-23","filed_date":"2024-01-25","scope":"insider"},{"id":3150818,"accession":"0000950170-24-002945","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000950170-24-002945","line_url":"/filing/0000950170-24-002945","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001834021","owner_name":"Kirn David","owner_display_name":"Kirn David","owner_url":"/insider/0001834021","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":28237.0,"shares_display":"28,237","price_per_share":19.565751949569712,"price_display":"19.57","price_state":"stated","total_value":552478.1378,"total_display":"552,478.14","total_whole":"552,478","shares_owned_after":1156983.0,"shares_owned_after_display":"1,156,983","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-05","filed_date":"2024-01-08","scope":"insider","n_lines":2},{"id":3150814,"accession":"0000950170-24-002945","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-002945","line_url":"/filing/0000950170-24-002945#line-3","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001834021","owner_name":"Kirn David","owner_display_name":"Kirn David","owner_url":"/insider/0001834021","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40732.0,"shares_display":"40,732","price_per_share":20.3084,"price_display":"20.31","price_state":"stated","total_value":827201.7488,"total_display":"827,201.75","total_whole":"827,202","shares_owned_after":1185087.0,"shares_owned_after_display":"1,185,087","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-04","filed_date":"2024-01-08","scope":"insider"},{"id":3150811,"accession":"0000950170-24-002945","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-002945","line_url":"/filing/0000950170-24-002945#line-2","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001834021","owner_name":"Kirn David","owner_display_name":"Kirn David","owner_url":"/insider/0001834021","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4702.0,"shares_display":"4,702","price_per_share":18.129,"price_display":"18.13","price_state":"stated","total_value":85242.558,"total_display":"85,242.56","total_whole":"85,243","shares_owned_after":1225819.0,"shares_owned_after_display":"1,225,819","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-18","filed_date":"2024-01-08","scope":"insider"},{"id":3150809,"accession":"0000950170-24-002945","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-002945","line_url":"/filing/0000950170-24-002945#line-1","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001834021","owner_name":"Kirn David","owner_display_name":"Kirn David","owner_url":"/insider/0001834021","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":28632.0,"shares_display":"28,632","price_per_share":17.2685,"price_display":"17.27","price_state":"stated","total_value":494431.692,"total_display":"494,431.69","total_whole":"494,432","shares_owned_after":1230521.0,"shares_owned_after_display":"1,230,521","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-15","filed_date":"2024-01-08","scope":"insider"},{"id":8211380,"accession":"0001567619-23-003706","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001567619-23-003706","line_url":"/filing/0001567619-23-003706#line-3","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001834021","owner_name":"Kirn David","owner_display_name":"Kirn David","owner_url":"/insider/0001834021","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16449.0,"shares_display":"16,449","price_per_share":20.224,"price_display":"20.22","price_state":"stated","total_value":332664.576,"total_display":"332,664.58","total_whole":"332,665","shares_owned_after":1859153.0,"shares_owned_after_display":"1,859,153","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-22","filed_date":"2023-02-23","scope":"insider"},{"id":8211379,"accession":"0001567619-23-003706","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-23-003706","line_url":"/filing/0001567619-23-003706","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001834021","owner_name":"Kirn David","owner_display_name":"Kirn David","owner_url":"/insider/0001834021","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17997.0,"shares_display":"17,997","price_per_share":20.959536806134356,"price_display":"20.96","price_state":"stated","total_value":377208.7839,"total_display":"377,208.78","total_whole":"377,209","shares_owned_after":1876509.0,"shares_owned_after_display":"1,876,509","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-21","filed_date":"2023-02-23","scope":"insider","n_lines":2},{"id":8634788,"accession":"0001567619-23-001163","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-23-001163","line_url":"/filing/0001567619-23-001163#line-2","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001834021","owner_name":"Kirn David","owner_display_name":"Kirn David","owner_url":"/insider/0001834021","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8625.0,"shares_display":"8,625","price_per_share":20.1886,"price_display":"20.19","price_state":"stated","total_value":174126.675,"total_display":"174,126.68","total_whole":"174,127","shares_owned_after":1893599.0,"shares_owned_after_display":"1,893,599","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-20","filed_date":"2023-01-23","scope":"insider"},{"id":8634785,"accession":"0001567619-23-001163","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-23-001163","line_url":"/filing/0001567619-23-001163#line-1","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001834021","owner_name":"Kirn David","owner_display_name":"Kirn David","owner_url":"/insider/0001834021","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10899.0,"shares_display":"10,899","price_per_share":20.0337,"price_display":"20.03","price_state":"stated","total_value":218347.2963,"total_display":"218,347.30","total_whole":"218,347","shares_owned_after":1902224.0,"shares_owned_after_display":"1,902,224","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-19","filed_date":"2023-01-23","scope":"insider"},{"id":6906512,"accession":"0001567619-22-021815","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001567619-22-021815","line_url":"/filing/0001567619-22-021815","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001834021","owner_name":"Kirn David","owner_display_name":"Kirn David","owner_url":"/insider/0001834021","role":"Director, Officer (Chief Executive Officer), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":53944.0,"shares_display":"53,944","price_per_share":23.016040823817292,"price_display":"23.02","price_state":"stated","total_value":1241577.3062,"total_display":"1,241,577.31","total_whole":"1,241,577","shares_owned_after":1939472.0,"shares_owned_after_display":"1,939,472","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-16","filed_date":"2022-12-19","scope":"insider","n_lines":2},{"id":6906505,"accession":"0001567619-22-021815","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-22-021815","line_url":"/filing/0001567619-22-021815","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001834021","owner_name":"Kirn David","owner_display_name":"Kirn David","owner_url":"/insider/0001834021","role":"Director, Officer (Chief Executive Officer), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":32933.0,"shares_display":"32,933","price_per_share":23.586275668782072,"price_display":"23.59","price_state":"stated","total_value":776766.8166,"total_display":"776,766.82","total_whole":"776,767","shares_owned_after":1968567.0,"shares_owned_after_display":"1,968,567","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-15","filed_date":"2022-12-19","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":27,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":27,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":27},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001650648","name":"4D Molecular Therapeutics, Inc.","url":"/issuer/0001650648","role":"Director, Officer, Ten percent owner","n_filings":14,"first_seen":"2022-12-19","last_seen":"2026-08-21"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001834021","retrieved_at":"2026-08-26T13:09:43+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}